Study of TL117 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
A phase 1/2 trial of Paclitaxel / nab-paclitaxel in head and neck squamous cell carcinoma, run by Suzhou Junde Biotechnology Co., Ltd, active and no longer recruiting.
Overview
Study of TL117 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma is a phase 1/2 interventional study registered as NCT04843098 by Suzhou Junde Biotechnology Co., Ltd, with 108 participants planned, started 2021-05-26 and due to reach its primary completion in 2024-11-20. Interventions recorded: TL117, Paclitaxel. Conditions listed: Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialStudy to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck
Shares Paclitaxel / nab-paclitaxel, Head and neck squamous cell carcinoma.
- TrialA Clinical Study of SI-B001 in Combination With Paclitaxel/Docetaxel in the Treatment of Recurrent and Metastatic HNSCC
Shares Paclitaxel / nab-paclitaxel, Head and neck squamous cell carcinoma.
- TrialA Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)
Shares Paclitaxel / nab-paclitaxel, Head and neck squamous cell carcinoma.
- TrialStudy of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Subst
Shares Paclitaxel / nab-paclitaxel, Head and neck squamous cell carcinoma.
- TrialStudy of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
Shares Paclitaxel / nab-paclitaxel, Head and neck squamous cell carcinoma.
- PersonAkhil Kapoor
Shares Paclitaxel / nab-paclitaxel, Head and neck squamous cell carcinoma.
- TrialAK129 Combination Therapy for Advanced Solid Tumors
Shares Paclitaxel / nab-paclitaxel, Head and neck squamous cell carcinoma.
- TrialA Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of
Shares Paclitaxel / nab-paclitaxel, Head and neck squamous cell carcinoma.